Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2009 2
2010 6
2011 4
2012 1
2013 8
2014 12
2015 3
2016 6
2017 10
2018 4
2019 4
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Catenacci DVT, et al. Lancet Oncol. 2017 Nov;18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1. Epub 2017 Sep 25. Lancet Oncol. 2017. PMID: 28958504 Free PMC article. Clinical Trial.
Study treatment was stopped early after an independent data monitoring committee found a higher number of deaths in the rilotumumab group than in the placebo group; all patients in the rilotumumab group subsequently discontinued all study treatment. ...The frequency …
Study treatment was stopped early after an independent data monitoring committee found a higher number of deaths in the rilotumumab g …
Potential role of rilotumumab in the treatment of gastric cancer.
Waddell T, Moorcraft SY, Cunningham D. Waddell T, et al. Immunotherapy. 2014;6(12):1243-53. doi: 10.2217/imt.14.91. Immunotherapy. 2014. PMID: 25524381 Review.
Rilotumumab is a monoclonal antibody directed against hepatocyte growth factor, the only known ligand for the MET receptor. It is an unlicensed product which is currently undergoing evaluation in a randomized Phase III trial in 'MET-positive' gastric cancer. Here we discus
Rilotumumab is a monoclonal antibody directed against hepatocyte growth factor, the only known ligand for the MET receptor. It is an
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J. Malka D, et al. Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23. Eur J Cancer. 2019. PMID: 31129386 Clinical Trial.
Adverse events grade ≥III occurred less frequently with chemotherapy alone (62%) than with panitumumab (83%) and rilotumumab (89%). CONCLUSIONS: We found no benefit in adding panitumumab or rilotumumab to mFOLFOX6 first-line chemotherapy to treat advanced gastroesop …
Adverse events grade ≥III occurred less frequently with chemotherapy alone (62%) than with panitumumab (83%) and rilotumumab (89%). C …
Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.
Zhang Y, Kuchimanchi M, Zhu M, Doshi S, Hoang T, Kasichayanula S. Zhang Y, et al. Br J Clin Pharmacol. 2017 May;83(5):1048-1055. doi: 10.1111/bcp.13179. Epub 2016 Dec 13. Br J Clin Pharmacol. 2017. PMID: 27966237 Free PMC article. Clinical Trial.
Rilotumumab PK was assessed by comparing the observed rilotumumab serum concentrations with model-predicted concentrations using a population PK model developed from previous Phase 1 and Phase 2 studies. ...CONCLUSIONS: The results suggest lack of PK-based DDI betwe
Rilotumumab PK was assessed by comparing the observed rilotumumab serum concentrations with model-predicted concentrations usi
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Doshi S, Gisleskog PO, Zhang Y, Zhu M, Oliner KS, Loh E, Perez Ruixo JJ. Doshi S, et al. Clin Cancer Res. 2015 Jun 1;21(11):2453-61. doi: 10.1158/1078-0432.CCR-14-1661. Epub 2015 Feb 24. Clin Cancer Res. 2015. PMID: 25712685 Free article. Clinical Trial.
Simulations were undertaken to predict the relationship between rilotumumab dose and OS. RESULTS: Rilotumumab exhibited linear time-independent pharmacokinetics not affected by MET expression. ...Rilotumumab exposure and change in tumor size from baseline at …
Simulations were undertaken to predict the relationship between rilotumumab dose and OS. RESULTS: Rilotumumab exhibited linear …
A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.
Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima TE, Tang R, Yang H, Zhang Y, Jung AS, Ang A, Yasui H. Doi T, et al. Jpn J Clin Oncol. 2017 Nov 1;47(11):1002-1009. doi: 10.1093/jjco/hyx114. Jpn J Clin Oncol. 2017. PMID: 28973403 Clinical Trial.
Rilotumumab pharmacokinetics appeared linear, and exposure was unaffected by CX. No patient who received rilotumumab monotherapy in Part 1 had a response. ...However, owing to the results of recent Phase 3 trials of MET inhibitors (including rilotumumab), fur
Rilotumumab pharmacokinetics appeared linear, and exposure was unaffected by CX. No patient who received rilotumumab monothera
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.
Zhang Y, Doshi S, Zhu M. Zhang Y, et al. Br J Clin Pharmacol. 2015 Nov;80(5):957-64. doi: 10.1111/bcp.12663. Epub 2015 May 26. Br J Clin Pharmacol. 2015. PMID: 25912961 Free PMC article. Review.
Rilotumumab is a fully human monoclonal antibody against hepatocyte growth factor, the only known ligand of the MET receptor. Over the last decade, rilotumumab has been extensively tested in preclinical studies and in clinical studies in a variety of cancer types. .
Rilotumumab is a fully human monoclonal antibody against hepatocyte growth factor, the only known ligand of the MET receptor. Over th
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M. Glisson B, et al. Clin Lung Cancer. 2017 Nov;18(6):615-625.e8. doi: 10.1016/j.cllc.2017.05.007. Epub 2017 May 10. Clin Lung Cancer. 2017. PMID: 28601388 Clinical Trial.
PATIENTS AND METHODS: In the phase 1b study, patients received rilotumumab 15 mg/kg or ganitumab 18 mg/kg with etoposide and carboplatin or cisplatin. In the phase 2 study, patients were randomly assigned 1:1:1 to receive placebo, rilotumumab, or ganitumab with etop …
PATIENTS AND METHODS: In the phase 1b study, patients received rilotumumab 15 mg/kg or ganitumab 18 mg/kg with etoposide and carbopla …
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.
Zhu M, Doshi S, Gisleskog PO, Oliner KS, Perez Ruixo JJ, Loh E, Zhang Y. Zhu M, et al. J Pharm Sci. 2014 Jan;103(1):328-36. doi: 10.1002/jps.23763. Epub 2013 Nov 1. J Pharm Sci. 2014. PMID: 24186235
To characterize rilotumumab pharmacokinetics in patients with cancer and to identify factors affecting the pharmacokinetics, rilotumumab concentration data from seven clinical trials were analyzed with a nonlinear mixed-effect model. ...The concentration-time profil …
To characterize rilotumumab pharmacokinetics in patients with cancer and to identify factors affecting the pharmacokinetics, rilot
Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.
Giordano S. Giordano S. Curr Opin Mol Ther. 2009 Aug;11(4):448-55. Curr Opin Mol Ther. 2009. PMID: 19649990
In preclinical studies, rilotumumab effectively blocked c-Met phosphorylation, inhibiting c-Met-activated downstream signaling pathways. In phase I clinical trials, rilotumumab was well tolerated at doses up to 20 mg/kg every 2 weeks. Data from preclinical studies a …
In preclinical studies, rilotumumab effectively blocked c-Met phosphorylation, inhibiting c-Met-activated downstream signaling pathwa …
56 results
Jump to page
Feedback